ReviewJournal of neuro-oncology2003
Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.
Review in Journal of neuro-oncology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 119 citations in OpenAlex.
- Trial
- The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors.International journal of molecular sciences · 2023Review
- Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.Frontiers in immunology · 2022Article
- Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.Neurosurgery clinics of North America · 2021Review
- Review
- Apoptosis-inducing effect of myxoma virus on human neuroglioma cell lines.Experimental and therapeutic medicine · 2017Article
- Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.Human gene therapy. Clinical development · 2016Article
- Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.Human gene therapy. Clinical development · 2014Article
- Glioblastoma multiforme: State of the art and future therapeutics.Surgical neurology international · 2014Review
- Gene therapy for malignant glioma.Molecular and cellular therapies · 2014Review
- Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.Frontiers in oncology · 2013Article
- Oncolytic viruses in the treatment of cancer: a review of current strategies.Pathology oncology research : POR · 2012Review
- Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.Journal of virology · 2012Article
- Advances in Gene Delivery Systems.Pharmaceutical medicine · 2011Article
- Gene therapy and targeted toxins for glioma.Current gene therapy · 2011Review
- Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery.Cancer gene therapy · 2011Article
- Herpesvirus vectors for therapy of brain tumors.The open virology journal · 2010Article
- Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Viral manipulation of DNA repair and cell cycle checkpoints.DNA repair · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Gene therapy using viral vectors for the treatment of primary brain tumors has proven to be a promising novel treatment modality. Much effort in the past has been placed in utilizing replication-defective viruses to this end but they have shown many disadvantages. Much recent attention has been focused on the potential of replication-competent viruses to discriminatingly target, replicate within, and destroy tumor cells via oncolysis, leaving adjacent post-mitotic neurons unharmed. The engineered tumor-selective herpes simplex-1 virus (HSV-1) mutants G207 and HSV1716 have completed Phase I investigations in the treatment of recurrent high-grade glioma. The results of these clinical trials are reviewed here. This review also aims to examine the manipulation and development of other viruses for the treatment of malignant glioma, including Newcastle disease virus, reovirus, poliovirus, vaccinia virus, and adenoviruses, in particular the adenovirus mutant ONYX-015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.